BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

BioNTech SE

BioNTech RNA Pharmaceuticals GmbH

At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. 

To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms.

We were founded in 2008 in Mainz, Germany and have been driven to become the leading global biotechnology company for individualized cancer medicine. We have over 20 product candidates in development, 8 candidates in 9 ongoing clinical trials, treated over 250 patients across 17 tumor types and supported by more than 1100 employees. 

As we prove the value of our approach in the clinic, we continue to build a network of world-class corporate and scientific collaborators, manufacturing and team required to bring individualized treatments to patients worldwide.

To learn more about us, visit https://biontech.de/

Our privacy statement can be found here: https://www.biontech.com/int/en/home/data-privacy-statement.html

🔬 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐚𝐭 #𝐀𝐀𝐂𝐑𝟐𝟎𝟐𝟒

We look forward to presenting updates for selected personalized #mRNA and targeted ADC #oncology candidates at the AACR Annual Meeting 2024 in San Diego, USA. This year’s data show how we’re delivering on our commitment of investigating novel treatment approaches to patients.
  
𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞:

𝐈𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐑𝐍𝐀-𝐛𝐚𝐬𝐞𝐝 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: longer-term follow-up data of activity and immune responses of the investigator-initiated first-in-human Phase 1 trial with our mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran (BNT122, RO7198457) in patients with resected pancreatic ductal adenocarcinoma (PDAC) 

𝐎𝐟𝐟-𝐭𝐡𝐞-𝐬𝐡𝐞𝐥𝐟 𝐦𝐑𝐍𝐀-𝐛𝐚𝐬𝐞𝐝 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: preliminary results on the LuCa-MERIT-1 Phase 1 trial with our off-the-shelf, shared tumor-associated-antigen-based mRNA therapeutic cancer vaccine candidate BNT116 in combination with docetaxel in patients with advanced unresectable or metastatic non-small cell lung cancer (NSCLC)

𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲-𝐝𝐫𝐮𝐠 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞𝐬 (𝐀𝐃𝐂𝐬): trial in progress poster on our global Phase 1/2a trial of the #ADC candidate BNT324/DB-1311 targeting the immune checkpoint protein B7H3 in patients with pretreated advanced or metastatic solid tumors

The full abstracts are available on the AACR Annual Meeting website. Further information on BioNTech’s pipeline candidates can be found on our website.

𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞:

+++𝗣𝗹𝗮𝗻𝗻𝗲𝗱 𝗥𝗲𝘁𝗶𝗿𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗼𝘂𝗿 𝗖𝗖𝗢 & 𝗖𝗕𝗢 𝗦𝗲𝗮𝗻 𝗠𝗮𝗿𝗲𝘁𝘁+++ 

After more than a decade of serving as Board Member in different roles, Sean Marett will retire this year as planned. A new CCO will be announced by the end of March 2024. His responsibilities as CBO are being gradually transferred to James Ryan, Ph.D., Chief Legal Officer who will also take on the role as BioNTech’s CBO at the end of the transition phase and upon Sean Marett’s retirement. As of July 1, 2024, Sean Marett will continue as a specialist advisor at least until the end of the year.     
 
👏 Sean's contributions to BioNTech's business development, fund-raising, and commercial activities have been crucial to our transformation into a next-generation immunotherapy company. Here are just a few of his accomplishments:  
 
● Various financing activities to ensure liquidity of over $1 billion, the largest Series A financing round for a biotech company at that stage worldwide. The activities were especially important for us in the first decade when we were a private company with pre-clinical programs.  
 
● Revenue-generating research and development agreements which Sean and his teams negotiated with high-profile pharmaceutical companies.  
 
● Complex global licensing and M&A transactions and strategic partnerships Sean and his teams reached with multiple governments, academic institutions, and charitable foundations.   

● Several supply agreements for our first product with governments.  
 
● The commercialization of the Pfizer-BioNTech COVID-19 Vaccine in Germany and Türkiye.  
 
Without Sean's determination, drive, and experience in aligning all stakeholders towards a common goal, BioNTech would not be the innovative company it is today. We're excited to see what the future holds with our new CCO, who will be announced by the end of March 2024.  
 
We’d like thank Sean in the name of the BioNTech family with a photo from your early days at BioNTech! #throwbackthursday  
 
https://lnkd.in/e-tuE25M

+++ 𝐌𝐞𝐞𝐭 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡’𝐬 𝐩𝐢𝐨𝐧𝐞𝐞𝐫𝐬: 𝐎𝐥𝐢𝐯𝐞𝐫 𝐇𝐞𝐧𝐧𝐢𝐠 +++

“I think what makes us very unique is that if we put our heads together and do it 100%, we can do it and we will get it done,” says Oliver Hennig, SVP Product Supply, about #TeamBiontech’s spirit. With this drive, we aspire to become an innovation leader in vaccine development and cancer precision medicine. 

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐞𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞

Since joining BioNTech in 2015, Oliver has worked on building and expanding our manufacturing and supply chain network to ensure our #therapy candidates and #vaccines reach those who need them most. During Project Lightspeed in 2020 and 2021, he was involved in building our commercial-scale manufacturing capabilities, which enabled us to successfully produce COVID-19 vaccine doses for worldwide distribution. Together with his teams, he is currently preparing commercial-scale manufacturing for potential future cancer therapies.  

𝑴𝒐𝒓𝒆 𝒐𝒑𝒑𝒐𝒓𝒕𝒖𝒏𝒊𝒕𝒊𝒆𝒔 𝒊𝒏 𝒑𝒓𝒐𝒅𝒖𝒄𝒕 𝒔𝒖𝒑𝒑𝒍𝒚 𝒇𝒐𝒓 𝒕𝒉𝒐𝒔𝒆 𝒘𝒉𝒐 𝒘𝒂𝒏𝒕 𝒕𝒐 𝒃𝒆𝒄𝒐𝒎𝒆 𝒑𝒂𝒓𝒕 𝒐𝒇 #𝑻𝒆𝒂𝒎𝑩𝒊𝒐𝑵𝑻𝒆𝒄𝒉: https://lnkd.in/dg49yN5S

+++ 𝗕𝗶𝗼𝗡𝗧𝗲𝗰𝗵 𝘀𝘁𝗿𝗶𝘃𝗲𝘀 𝘁𝗼 𝗯𝗿𝗶𝗻𝗴 𝗖𝗔𝗥-𝗧 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘁𝗼 𝗺𝗼𝗿𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿 𝘄𝗶𝘁𝗵 𝗔𝘂𝘁𝗼𝗹𝘂𝘀 +++

We have been active in the development of cell and gene therapies since 2009 and the technology has become one of our core platform technologies. Today, we announce a collaboration with Autolus Therapeutics which aims to support us further in our objective to become a leader in the field by developing cell therapies potentially addressing various tumor types. 

𝙍𝙚𝙖𝙙 𝙢𝙤𝙧𝙚 𝙤𝙣 𝙩𝙝𝙚 𝙨𝙩𝙧𝙖𝙩𝙚𝙜𝙞𝙘 𝙘𝙤𝙡𝙡𝙖𝙗𝙤𝙧𝙖𝙩𝙞𝙤𝙣: 

𝐓𝐨𝐠𝐞𝐭𝐡𝐞𝐫, 𝐰𝐞 𝐚𝐫𝐞 𝐚𝐢𝐦𝐢𝐧𝐠 𝐭𝐨 𝐬𝐡𝐚𝐩𝐞 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 𝐜𝐚𝐫𝐞. 🔬 🚀 

We, #TeamBioNTech, strive to develop novel precision and personalized medicines that, if successfully developed and approved, have the potential to address #cancer across all stages of the disease along the patient journey -- from early disease to advanced, recurrent disease stages, where the medical need remains high. 

Our clinical-stage therapy toolkit was established with the aim to overcome current limitations in the treatment of many cancer types:  

𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐑𝐍𝐀 𝐜𝐚𝐧𝐜𝐞𝐫 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞𝐬: tailored to the genetic background of a patient’s tumor or tumor type with the aim to prevent or delay disease recurrence in early stages 

𝐂𝐀𝐑-𝐓 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬: engineered T cells targeted to a specific structure on the cancer cell which are combined with a CAR-T cell amplifying mRNA vaccine aimed at treating patients in advanced disease stages 

𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲-𝐝𝐫𝐮𝐠 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞 (𝐀𝐃𝐂) 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞𝐬: a targeted chemotherapy approach aimed at combining the selectivity of antibodies with the cancer cell-killing properties of chemotherapy in intermediate to advanced disease stages 

﻿𝐈𝐦𝐦𝐮𝐧𝐞 𝐜𝐡𝐞𝐜𝐤𝐩𝐨𝐢𝐧𝐭 𝐦𝐨𝐝𝐮𝐥𝐚𝐭𝐨𝐫𝐬: mono- or bispecific antibody candidates aimed at boosting antitumor immune responses in metastatic or advanced disease stages
 
Today, on #WorldCancerDay, we want to introduce some of the pioneers driving the change in #CancerCare: 👇 

+++𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐍𝐞𝐰𝐬: 𝐅𝐃𝐀 𝐅𝐚𝐬𝐭 𝐓𝐫𝐚𝐜𝐤 𝐝𝐞𝐬𝐢𝐠𝐧𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐁𝐍𝐓𝟑𝟐𝟓+++

We just reached another landmark in our oncology pipeline of innovative precision medicine candidates: The US Food and Drug Administration (FDA) granted Fast Track designation for our antibody-drug conjugate (ADC) candidate BNT325/DB-1305 for the treatment of patients with advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. BNT325 is the second asset in our strategic collaboration with Duality Biologics which has received FDA Fast Track designation, highlighting the potential of the candidate to fill an unmet medical need. 

𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐧𝐞𝐞𝐝
Ovarian cancer is the fourth most common gynecological tumor type, with over 300,000 cases diagnosed globally each year. Epithelial #OvarianCancer — the most common ovarian cancer — develops in tissue surrounding the ovaries. It includes fallopian tube cancer and primary peritoneal cancer. Ovarian epithelial #cancer is often diagnosed at advanced disease stages, leading to a poor prognosis for patients and making it one of the most frequent causes of cancer death in women.[1] 

𝐀𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞
BNT325 is a next-generation ADC candidate targeting the trophoblast cell-surface antigen 2 (TROP2), a protein which is overexpressed on a range of tumor types and linked to aggressive tumor growth and progression.[2] BNT325 is designed with the aim to combine a TROP2-trageted antibody with the cell-killing properties of an anti-cancer drug (chemo). 

[1] Havasi A et al. Medicina (Kaunas). 2023 Mar; 59(3): 544. 
[2] Wen Y, Ouyang D et al. Ann Transl Med. 2022 Dec; 10(24): 1403. 

𝑹𝒆𝒂𝒅 𝒎𝒐𝒓𝒆: https://lnkd.in/dhHeydkb

DE:BIONTECH

BioNTech SE

Last Close

108.23

22/11 21:00

Market Cap

19.33B

Beta: -

Volume Today

1.19M

Avg: -

Financials Not Available